Significance of HLA-B[]51 allele expression in Crohn's disease: a case-control study

OBJECTIVESCrohn's disease (CD) and Behçet's disease (BD) are two autoinflammatory diseases that share clinical and pathogenic features. Furthermore, when BD involves the gastrointestinal tract, it is extremely difficult to distinguish endoscopic lesions from CD lesions. HLA-B*51 allele exp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental rheumatology 2023-10, Vol.41 (10), p.2044-2047
Hauptverfasser: Kostianovsky, Alex, Llanquimán, Pablo E., Olivera, Pablo A., Muñoz, Sebastián A., Gandino, Ignacio, Orden, Alberto O., Dal Pra, Fernando, Teper, Sara, Khoury, Marina C., Sambuelli, Alicia M., Allievi, Alberto
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:OBJECTIVESCrohn's disease (CD) and Behçet's disease (BD) are two autoinflammatory diseases that share clinical and pathogenic features. Furthermore, when BD involves the gastrointestinal tract, it is extremely difficult to distinguish endoscopic lesions from CD lesions. HLA-B*51 allele expression is highly associated with BD diagnosis. In this study we analysed HLA-B*51 status in 70 Argentine patients with confirmed CD diagnosis and compared it to our previous Argentine BD cohort, with the aim of finding similarities or differences between these two diseases regarding HLA-B*51 status.METHODSThis is a multi-centre case-control study, including 70 patients with confirmed CD diagnosis, who underwent HLA-B*51 allele status testing; the results were compared to our previous BD cohort of 34 patients.RESULTSAmong patients with CD, 12.85% were positive for the HLA-B*51 allele, compared with 38.24% patients with BD (OR=0.238; 95% CI=0.089-0.637; p=0.004).CONCLUSIONSOur finding suggests that determination of HLA-B*51 allele status may contribute to the differential diagnosis between CD and BD.
ISSN:1593-098X
0392-856X
1593-098X
DOI:10.55563/clinexprheumatol/yr9c5h